8-K: Amphastar Reports Q4, Full-Year 2025 Results

Amphastar Pharmaceuticals announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, highlighting BAQSIMI's continued growth and new product approvals amidst overall revenue decline.

Summary

• Net revenues for the three months ended December 31, 2025, were $183.1 million, a 2% decrease compared to $186.5 million in the prior year period.
• Full fiscal year 2025 net revenues were $719.9 million, a 2% decrease from $732.0 million in fiscal year 2024.
• GAAP net income for Q4 2025 was $24.4 million, or $0.51 per diluted share, down from $38.0 million, or $0.74 per diluted share, in Q4 2024.
• Full fiscal year 2025 GAAP net income was $98.1 million, or $2.03 per diluted share, a significant decrease from $159.5 million, or $3.06 per diluted share, in fiscal year 2024.
• Adjusted non-GAAP net income for Q4 2025 was $34.2 million, or $0.73 per diluted share, compared to $47.2 million, or $0.92 per diluted share, in Q4 2024.
• Full fiscal year 2025 adjusted non-GAAP net income was $156.6 million, or $3.25 per diluted share, down from $200.8 million, or $3.86 per diluted share, in fiscal year 2024.
• BAQSIMI sales increased by 12% in Q4 2025 to $46.7 million and by 46% for the full year 2025 to $185.4 million, maintaining momentum as a top revenue driver.
• Glucagon sales decreased significantly by 45% in Q4 and 36% for the full year due to lower pricing and unit volumes, impacted by competition and a shift to ready-to-use products.
• Epinephrine sales decreased by 9% in Q4 and 25% for the full year, primarily due to increased competition for the multi-dose vial product.
• FDA approvals were received for iron sucrose injection and teriparatide injection, demonstrating technical capabilities in complex generics.
• The company expanded its long-term strategic vision by adding three novel peptides and a fully synthetic corticotropin compound to its pipeline, targeting oncology, ophthalmology, and immunology.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant declines in overall revenue and profitability, offset by strong performance in BAQSIMI and strategic pipeline expansion, indicating underlying challenges but also future growth potential.

Positives

• BAQSIMI maintained strong commercial momentum with double-digit growth, increasing 12% in Q4 2025 to $46.7 million and 46% for the full year 2025 to $185.4 million.
• Received FDA approvals for iron sucrose injection (launched August 2025) and teriparatide injection, showcasing depth in complex generics.
• Expanded proprietary pipeline by in-licensing three novel peptides for oncology and ophthalmology, and a fully synthetic corticotropin compound for inflammatory and autoimmune conditions.
• Increased sales of albuterol by $4.2 million in Q4 2025 and $14.7 million for the full year 2025.
• Increased sales of iron sucrose by $2.0 million in Q4 2025 and $4.4 million for the full year 2025, following its August 2025 launch.
• Experienced increased sales of sodium bicarbonate and atropine due to demand caused by shortages from other suppliers.
• Cash flow provided by operating activities for the year ended December 31, 2025, was $156.1 million.

Negatives

• Total net revenues decreased by 2% for both the three months and full fiscal year ended December 31, 2025, compared to the prior year.
• GAAP net income decreased by 35.7% in Q4 2025 and 38.5% for FY 2025.
• Adjusted non-GAAP net income decreased by 27.6% in Q4 2025 and 22.0% for FY 2025.
• Glucagon sales decreased significantly by 45% in Q4 2025 and 36% for FY 2025, primarily due to lower average selling price and unit volumes from competition and a shift to ready-to-use products.
• Epinephrine sales decreased by 9% in Q4 2025 and 25% for FY 2025, mainly due to lower unit volumes and average selling price for the multi-dose vial product from increased competition.
• Primatene MIST sales decreased by 3% in Q4 2025 due to lower unit volumes.
• General and administrative expenses increased by 51% for FY 2025, primarily due to a $23.1 million legal settlement and expenses related to a new ERP system implementation.
• Research and development expenses increased by 16% for FY 2025, driven by clinical trial expenses for insulin and inhalation pipeline products, and a $6.0 million upfront payment for a licensing agreement.
• Other income, net, decreased significantly by 99% for FY 2025, primarily due to foreign currency fluctuation and mark-to-market adjustments relating to interest rate swap contracts.
• Interest income decreased by 18% for FY 2025 due to lower interest rates on cash and investments accounts.
• Sales of enoxaparin decreased by $9.9 million and dextrose by $9.6 million for FY 2025 due to increased competition.

Risks

• Increased competition impacting sales volumes and average selling prices for key products such as Epinephrine and Glucagon.
• Foreign currency fluctuations and mark-to-market adjustments on interest rate swap contracts can negatively affect non-operating income.
• The success of sales strategies, particularly for BAQSIMI, is not guaranteed and actual sales may differ from expectations.
• Uncertainties and assumptions inherent in product development, including the timing of FDA filings or approvals and clinical trial results.
• General risks associated with the biopharmaceutical industry, as detailed in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company is committed to advancing its pipeline programs, securing upcoming approvals, and scaling U.S.-based manufacturing in 2026 to support the next phase of growth. The proprietary pipeline includes four recently in-licensed products: three novel peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound for inflammatory and autoimmune conditions. The company also has one ANDA and one biosimilar insulin candidate filed with the FDA, two biosimilar products in development, and two generic products in development, targeting combined market sizes exceeding $1.7 billion, $3.7 billion, and $1 billion, respectively.

Management Comments

• "2025 underscored Amphastar's evolution into a company focused on both commercial strength and scientific innovation." Dr. Jack Zhang, President and Chief Executive Officer.
• "On the commercial side, BAQSIMI maintained its momentum as a top revenue driver with sustained double-digit growth, while the FDA approvals of our iron sucrose injection and our teriparatide injection demonstrate the depth of our technical capabilities in complex generics and ability to leverage our in-house manufacturing expertise to deliver high-quality, affordable therapies to patients." Dr. Jack Zhang.
• "We also furthered our long-term strategic vision by adding three novel peptides and a fully synthetic corticotropin compound to expand our presence in oncology, ophthalmology, and immunology." Dr. Jack Zhang.
• "As we look ahead to 2026, we remain committed to advancing these programs, securing upcoming approvals, and scaling our U.S. based manufacturing to support the next phase of our growth." Dr. Jack Zhang.

Industry Context

StockSavvy.ai notes that Amphastar's strategy of leveraging in-house manufacturing expertise for technically challenging generic and proprietary injectables aligns with a broader industry trend towards vertical integration and cost control in the biopharmaceutical sector. The focus on expanding into oncology, ophthalmology, and immunology with novel peptides and corticotropin compounds indicates a strategic move towards higher-value, specialized markets, diversifying beyond mature generic segments facing intense competition, as evidenced by declines in glucagon and epinephrine sales.

Legal Proceedings

• A legal settlement increased general and administrative expenses by $23.1 million for the fiscal year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Experienced significant decreases in GAAP and non-GAAP net income and diluted EPS, potentially impacting short-term returns, but pipeline expansion offers long-term growth prospects.
• Customers: Benefit from continued access to high-quality, affordable therapies, including newly FDA-approved products like iron sucrose and teriparatide.
• Employees: Potential for growth in manufacturing and R&D sectors as the company scales operations and advances its product pipeline.
• Competitors: Increased competition has negatively impacted Amphastar's sales and pricing for certain products, indicating a dynamic and challenging market environment.

Next Steps

• Hold a conference call on February 26, 2026, at 2:00 p.m. Pacific Time to discuss financial results.
• Advance pipeline programs, including one ANDA, one biosimilar insulin candidate, two biosimilar products, and two generic products in development.
• Secure upcoming approvals for pipeline products.
• Scale U.S.-based manufacturing to support future growth.

Key Dates

Recommendation

While BAQSIMI's strong growth and strategic pipeline additions offer long-term potential, the significant declines in overall revenue and profitability, driven by competitive pressures on other key products and substantial one-time expenses like the legal settlement, warrant a cautious approach. The company is in a transitional phase, balancing established product challenges with future growth investments. Investors should hold to observe the execution of pipeline advancements and the impact of new product launches on overall financial performance.

Keywords

Pharmaceuticals, Biopharmaceutical, Generic Drugs, Injectable Products, Inhalation Products, Intranasal Products, BAQSIMI, Epinephrine, Glucagon, Primatene MIST, Financial Results, SEC Filing, AMPH, Q4 2025, Full Year 2025, Drug Development, FDA Approvals, Pipeline, Oncology, Ophthalmology, Immunology